ZBTB16
Overview
ZBTB16 (Zinc Finger and BTB Domain Containing 16), also known as PLZF (promyelocytic leukaemia zinc finger), is an androgen-regulated transcription factor. In metastatic castration-resistant prostate cancer (mCRPC), a novel recurrent focal homozygous deletion at chr11q23 affecting ZBTB16 was identified in 8 of 150 cases (5%). Preclinical models link ZBTB16 loss to androgen resistance and MAPK pathway upregulation.
Alterations observed in the corpus
- Novel recurrent focal homozygous deletion at chr11q23 in 8/150 (5%) of mCRPC cases (WGS/WES); ZBTB16 (PLZF) is androgen-regulated; preclinical models link loss to androgen resistance and MAPK pathway upregulation. PMID:26000489
- ZBTB16, along with FOXA1, NCOR1, and NCOR2, identified as an AR co-activator whose alteration is enriched in CRPC-Adeno (21 cases) relative to CRPC-NE PMID:26855148
- Recurrent mCRPC driver mutation consistent with prior reports; identified among pan-metastasis driver genes in a rapid-autopsy whole-genome sequencing cohort PMID:26928463
Cancer types (linked)
- PRAD (mCRPC): Focal homozygous deletion in 5% of metastatic castration-resistant prostate cancer cases; novel finding not previously characterised in mCRPC. PMID:26000489
Co-occurrence and mutual exclusivity
- No specific co-occurrence or mutual exclusivity patterns with other mCRPC drivers reported in the corpus.
Therapeutic relevance
- Potential connection to androgen resistance and MAPK pathway activation; ZBTB16 loss may inform combination AR-directed and MEK inhibitor strategies. Functional validation of this mechanism required. PMID:26000489
Open questions
- Functional significance of ZBTB16 deletion in mCRPC biology (androgen resistance, MAPK upregulation) awaits exploration in organoid and preclinical systems. PMID:26000489
Sources
This page was processed by crosslinker on 2026-05-14. - PMID:26855148
This page was processed by wiki-cli on 2026-05-14. - PMID:26928463
This page was processed by wiki-cli on 2026-05-14.